Skip to main content
OpenTrials
Completed

NCT Number: NCT01953861

A Study to Evaluate Whether Food Has an Effect on the Uptake of Solifenacin and Tamsulosin When Administered in a Combination Tablet

To evaluate the effect of food (low and high fat breakfast vs. fasting) on the pharmacokinetics (what the body does to the drug) of a single dose of solifenacin and tamsulosin administered as combination tablet EC905. Also to evaluate the safety and tolerability of single doses of EC905 in young, healthy male subjects, when administered under fed (low and high fat) or fasting conditions.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

EC905 Healthy Subjects Pharmacokinetics

Age range

18 year–55 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Parexel Early Phase Clinical Unit

Harrow, H1 3UJ, United Kingdom

About this study

Subjects are admitted to the clinic on Day -1 and receive a single dose of the combination tablet EC905 on the first day of 3 periods, under three conditions (high fat breakfast, low fat breakfast, and fasting) in order to evaluate the effect of food.

Blood sampling for pharmacokinetic (PK) assessment is performed on the dosing day and for 11 days after dosing in each period. This 11-day on-site period is repeated three times so that all subjects are dosed under all conditions. Each period is separated by 7 days off site.

Subjects return for an End of Study Visit (ESV) at least 7 days after the last 11 day on-site period, or after withdrawal.

On Day 1 of each of 3 periods, subjects are given a single dose of EC905 under three conditions (high fat breakfast, low fat breakfast and fasting) in order to evaluate the effect of food on the PK of solifenacin and tamsulosin HCl. The aim is to show the absence of a food effect after a low fat breakfast vs. fasting conditions, and to evaluate the food effect after a high fat breakfast vs. fasting conditions.

Subjects are randomized to one of 6 possible sequences of fasted or fed conditions.

Screening takes place from Day -21 to Day -1. They are admitted to the clinic on Day -1. Blood sampling for PK assessment is performed from Day 1 to Day 11 of each period. This 11 day on-site period is repeated three times in order to allow all subjects to be dosed under fed (low and high fat) and fasting conditions.

The 11 day on-site periods are separated by 7-day off site periods; subjects are checked for eligibility again one day prior to the start of a new dosing day.

Safety assessments are performed throughout the investigational period. Subjects return for an ESV at least 7 days after the last 11 day on-site period, or after withdrawal.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • BMI between 18.5 and 30.0 kg/m2, inclusive.

Exclusion criteria

  • Known or suspected hypersensitivity to solifenacin, tamsulosin or any of the other recipients of EC905.
  • Any of the contraindications or precautions for use as mentioned in the applicable sections of the Summary of Product Characteristics (SPC) of tamsulosin or solifenacin
  • Use of grapefruit (more than 3 x 200 ml) or marmalade (more than three times) in the week prior to admission to the Clinical Unit, as reported by the subject.

Treatment and study plan

EC905

Drug

Oral

Other names: Vesomni, VesiFlow, Urizia

Primary outcomes

  1. Pharmacokinetic parameter of solifenacin by Area Under the Curve from the time of dosing until the last measurable concentration (AUClast) in plasma

    Time frame: Days 1-11, 18-28, 35-45

    area under the plasma concentration - time curve (AUC) from the time of dosing until the last measurable concentration (AUClast)

  2. Pharmacokinetic parameter of solifenacin by maximum concentration (Cmax) in plasma

    Time frame: Days 1-11, 18-28, 35-45

    maximum concentration (Cmax)

  3. Pharmacokinetic parameter of tamsulosin HCl by Area Under the Curve from the time of dosing until the last measurable concentration (AUClast) in plasma

    Time frame: Days 1-11, 18-28, 35-45

    area under the plasma concentration - time curve (AUC) from the time of dosing until the last measurable concentration (AUClast)

  4. Pharmacokinetic parameter of tamsulosin HCl by maximum concentration (Cmax) in plasma

    Time frame: Days 1-11, 18-28, 35-45

    maximum concentration (Cmax)

Secondary outcomes

  1. Pharmacokinetics profile of solifenacin concentration: (AUCinf), (t1/2), (tmax), (CL/F) and (Vz/F)

    Time frame: Days 1-11, 18-28, 35-45

    (plasma) AUC extrapolated until time = infinity (AUCinf), apparent terminal elimination half-life (t1/2), time to attain Cmax (tmax), apparent total body clearance (CL/F), apparent volume of distribution during the terminal phase (Vz/F)

  2. Pharmacokinetics profile of tamsulosin HCl concentration: (AUCinf), (t1/2), (tmax), (CL/F) and (Vz/F)

    Time frame: Days 1-11, 18-28, 35-45

    (plasma) AUC extrapolated until time = infinity (AUCinf), apparent terminal elimination half-life (t1/2), time to attain Cmax (tmax), apparent total body clearance (CL/F), apparent volume of distribution during the terminal phase (Vz/F)

  3. Safety and tolerability of single doses of EC905 (solifenacin/tamsulosin HCl) under fed or fasted conditions

    Time frame: Screening (Day-21 to -1) to ESV (at least 7 days after the last 11 day on-site period, or after withdrawal)

    Adverse events, clinical laboratory tests, vital signs, electrocardiogram (ECG), physical examination

Sponsors and collaborators

Lead sponsor

Astellas Pharma Europe B.V.

Industry

Registry information

Official study title

An Open-label, Single Dose, Randomized, Three-way Cross-over Study to Evaluate the Effect of Food on the Pharmacokinetics of Solifenacin and Tamsulosin Administered as Combination Tablet EC905 in Young, Healthy Male Subjects

Important dates

Study start
2010
Primary completion
2010
Study completion
2010
First posted
Oct 1, 2013
Registry last updated
May 29, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.